Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT

Abstract

Several T-cell depletion (TCD) techniques are used for haploidentical hematopoietic SCT (HSCT), but direct comparisons are rare. We therefore studied the effect of in vitro TCD with graft engineering (CD34 selection or CD3/CD19 depletion, 74%) or in vivo TCD using alemtuzumab (26%) on outcome, immune reconstitution and infections after haploidentical HSCT. We performed a retrospective multicenter analysis of 72 haploidentical HSCT in Switzerland. Sixty-seven patients (93%) had neutrophil engraftment. The 1-year OS, TRM and relapse incidence were 48 (36–60)%, 20 (11–33)% and 42 (31–57)%, respectively, without differences among the TCD groups. In vivo TCD caused more profound lymphocyte suppression early after HSCT, whereas immune recovery beyond the second month was comparable between the two groups. Despite anti-infective prophylaxis, most patients experienced post-transplant infectious complications (94%). Patients with in vivo TCD had a higher incidence of CMV reactivations (54% vs 28%, P=0.015), but this did not result in a higher TRM. In conclusion, TCD by graft engineering or alemtuzumab are equally effective for haploidentical HSCT.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Passweg J, Baldomero H, Stern M, Bargetzi M, Ghielmini M, Leibundgut K et al. Hematopoietic stem cell transplantation in Switzerland: a comprehensive quality control report on centre effect. Swiss Med Wkly 2010; 140: 326–334.

    PubMed  Google Scholar 

  2. Symons HJ, Fuchs EJ . Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors. Bone Marrow Transplant 2008; 42: 365–377.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Aversa F . Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant 2008; 41: 473–481.

    Article  CAS  PubMed  Google Scholar 

  4. Reisner Y, Martelli MF . From ‘megadose’ haploidentical hematopoietic stem cell transplants in acute leukemia to tolerance induction in organ transplantation. Blood Cells Mol Dis 2008; 40: 1–7.

    Article  PubMed  Google Scholar 

  5. Hagin D, Reisner Y . Haploidentical bone marrow transplantation in primary immune deficiency: stem cell selection and manipulation. Hematol Oncol Clin North Am 2011; 25: 45–62.

    Article  PubMed  Google Scholar 

  6. Koh L-P, Chao N . Haploidentical hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42 (Suppl 1): S60–S63.

    Article  PubMed  Google Scholar 

  7. Kanda Y, Oshima K, Asano-Mori Y, Kandabashi K, Nakagawa M, Sakata-Yanagimoto M et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 2005; 79: 1351–1357.

    Article  CAS  PubMed  Google Scholar 

  8. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25: 690–697.

    Article  CAS  PubMed  Google Scholar 

  9. Chakrabarti S, Hale G, Waldmann H . Alemtuzumab (Campath–1H) in allogeneic stem cell transplantation: where do we go from here? Transplant Proc 2004; 36: 1225–1227.

    Article  CAS  PubMed  Google Scholar 

  10. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  12. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  13. Kanda J, Chao NJ, Rizzieri DA . Haploidentical transplantation for leukemia. Curr Oncol Rep 2010; 12: 292–301.

    Article  PubMed  Google Scholar 

  14. Chalandon Y, Roosnek E, Mermillod B, Waelchli L, Helg C, Chapuis B . Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study. Biol Blood Marrow Transplant 2006; 12: 102–110.

    Article  PubMed  Google Scholar 

  15. Spitzer T . Haploidentical Stem Cell Transplantation: The Always Present but Overlooked Donor. Hematology 2005; 2005: 390.

    Article  Google Scholar 

  16. Lang P, Handgretinger R . Haploidentical SCT in children: an update and future perspectives. Bone Marrow Transplant 2008; 42 (Suppl 2): S54–S59.

    Article  PubMed  Google Scholar 

  17. Federmann B, Hägele M, Pfeiffer M, Wirths S, Schumm M, Faul C et al. Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts. Leukemia 2011; 25: 121–129.

    Article  CAS  PubMed  Google Scholar 

  18. Chang Y-J, Zhao X-Y, Huo M-R, Xu L-P, Liu D-H, Liu K-Y et al. Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies. Am J Hematol 2011; 86: 227–230.

    Article  PubMed  Google Scholar 

  19. Dodero A, Carniti C, Raganato A, Vendramin A, Farina L, Spina F et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 2009; 113: 4771–4779.

    Article  CAS  PubMed  Google Scholar 

  20. Stern M, Ruggeri L, Mancusi A, Bernardo ME, de Angelis C, Bucher C et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008; 112: 2990–2995.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 2010; 115: 3437–3446.

    Article  CAS  PubMed  Google Scholar 

  22. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  PubMed  Google Scholar 

  23. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008; 112: 3574–3581.

    Article  CAS  PubMed  Google Scholar 

  24. Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis 2008; 40: 13–19.

    Article  CAS  PubMed  Google Scholar 

  25. Champlin RE, Passweg JR, Zhang MJ, Rowlings PA, Pelz CJ, Atkinson KA et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 2000; 95: 3996–4003.

    CAS  PubMed  Google Scholar 

  26. Lee SJ, Zahrieh D, Alyea EP, Weller E, Ho VT, Antin JH et al. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood 2002; 100: 2697–2702.

    Article  CAS  PubMed  Google Scholar 

  27. Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol 2012; 30: 3194–3201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855–864.

    Article  CAS  PubMed  Google Scholar 

  29. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, Di Bartolomeo P et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98: 2942–2947.

    Article  CAS  PubMed  Google Scholar 

  30. Barge RMY, Starrenburg CWJ, Falkenburg JHF, Fibbe WE, Marijt EW, Willemze R . Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath ‘in the bag’ as T-cell depletion: the Leiden experience. Bone Marrow Transplant 2006; 37: 1129–1134.

    Article  CAS  PubMed  Google Scholar 

  31. Lang P, Schumm M, Greil J, Bader P, Klingebiel T, Müller I et al. A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients: preliminary results of a pilot study. Klin Padiatr 2005; 217: 334–338.

    Article  CAS  PubMed  Google Scholar 

  32. Chen X, Hale GA, Barfield R, Benaim E, Leung WH, Knowles J et al. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. Br J Haematol 2006; 135: 524–532.

    Article  PubMed  Google Scholar 

  33. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447–3454.

    Article  PubMed  Google Scholar 

  34. Bühlmann L, Buser AS, Cantoni N, Gerull S, Tichelli A, Gratwohl A et al. Lymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCT. Bone Marrow Transplant 2010; 46: 1357–1362.

    Article  PubMed  Google Scholar 

  35. Wendtner C-M, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jäger G et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission—experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004, 1093–1101.

    Article  CAS  PubMed  Google Scholar 

  36. Schmidt-Hieber M, Schwarck S, Stroux A, Ganepola S, Reinke P, Thiel E et al. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int J Hematol 2010; 91: 877–885.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all the transplant teams at the four centers for their continuous support of the patients.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to G Stussi.

Ethics declarations

Competing interests

The authors declare no conflict of intrest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marek, A., Stern, M., Chalandon, Y. et al. The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. Bone Marrow Transplant 49, 55–61 (2014). https://doi.org/10.1038/bmt.2013.132

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2013.132

Keywords

This article is cited by

Search

Quick links